Ambit Biosciences
Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.
Afraxis, Inc. is a contract research organization based in San Diego, California, that specializes in preclinical efficacy evaluations, including both in vivo and in vitro methods, as well as neurotoxicity evaluations and structure-efficacy relationship-driven medicinal chemistry. The company utilizes its enhanced spine profiling technology to deliver rapid and detailed insights into synaptic networks from various tissue preparations. This technology includes specialized neuron labeling, high-resolution imaging, and advanced statistical methods for interpreting large data sets. Afraxis also provides in vivo high-content analysis services, encompassing live cell imaging and N-dimensional analysis. In addition to these services, the company is involved in drug discovery, focusing on developing treatments for central nervous system disorders such as schizophrenia, Alzheimer's disease, Fragile X syndrome, and autism spectrum disorders. Founded in 2007, Afraxis is dedicated to advancing research in neuropharmacology and assessing potential adverse cognitive impacts related to drug development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.